SEC Form 4 · accession 0001179110-15-012500
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Laurie Stelzer
Officer — Chief Financial Officer
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 8:46 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2 | Aug 20, 2015 | P | 10,000 | $17.2384 | A | 10,000 | I | By trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is the average weighted price. The shares were sold in multiple transactions at prices ranging from $17.21 to $17.25, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were purchased.
- F2The reporting person is co-trustee of the Gregory and Laureen Stelzer Living Trust.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney